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Abstract
Background
NGS-based genetic diagnosis has completely revolutionized the human genetics field. In
this study, we have aimed to identify new genes and mutations by Whole Exome Sequenc-
ing (WES) responsible for inherited retinal dystrophies (IRD).
Methods
A cohort of 33 pedigrees affected with a variety of retinal disorders was analysed by WES.
Initial prioritization analysis included around 300 IRD-associated genes. In non-diagnosed
families a search for pathogenic mutations in novel genes was undertaken.
Results
Genetic diagnosis was attained in 18 families. Moreover, a plausible candidate is proposed
for 10 more cases. Two thirds of the mutations were novel, including 4 chromosomal rear-
rangements, which expand the IRD allelic heterogeneity and highlight the contribution of pri-
vate mutations. Our results prompted clinical re-evaluation of some patients resulting in
assignment to a syndromic instead of non-syndromic IRD. Notably, WES unveiled four new
candidates for non-syndromic IRD: SEMA6B, CEP78, CEP250, SCLT1, the two latter
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previously associated to syndromic disorders. We provide functional data supporting that
missense mutations in CEP250 alter cilia formation.
Conclusion
The diagnostic efficiency of WES, and strictly following the ACMG/AMP criteria is 55% in
reported causative genes or functionally supported new candidates, plus 30% families in
which likely pathogenic or VGUS/VUS variants were identified in plausible candidates. Our
results highlight the clinical utility of WES for molecular diagnosis of IRD, provide a wider
spectrum of mutations and concomitant genetic variants, and challenge our view on syndro-
mic vs non-syndromic, and causative vs modifier genes.
Introduction
Massive sequencing, particularly Whole Exome Sequencing (WES), has completely revolution-
ized genetic diagnosis of highly heterogeneous monogenic disorders. In the field of inherited
retinal disorders (IRD), more than 20 novel genes, mostly identified by WES, have been
reported since the beginning of 2014 (an average of one novel gene per month). This success
relies on the power of primary sequence DNA data at a genomic scale, the increasing number
of suitable up-to-date databases of SNP allelic frequencies in different populations, the relative
simplicity of standardized WES protocols and the availability of powerful and increasingly
refined bioinformatics tools [1–4].
The molecular diagnosis yield of WES is highly empowered by complementary genetic data
(e.g. homozygosity mapping and linkage analysis), which greatly favours the identification of
the causative gene in recessive cases. In contrast, finding the pathogenic mutation in dominant
cases amidst the high number of heterozygous variants identified by WES is far from trivial,
and often requires cosegregation analysis in large pedigrees, which are not always available nei-
ther necessarily conclusive [5–8].
Molecular diagnosis of IRD is one of the main aims of our research. Currently, aside WES,
other massive sequencing-based approaches have been also implemented in IRD genetic diag-
nosis laboratories, such as targeted-sequencing of a limited set of causative/candidate genes
[9–12]. These approaches have proved useful to study large cohorts in order to identify
reported or novel mutations in known genes, but they may fall short when the pathogenic
mutation maps in an unreported candidate. Increasing the number of analysed genes greatly
redounds in the final diagnostic efficiency, broadens the spectrum of the cellular pathways
underlying the retinal pathological state, provides invaluable insights into phenotype-modifier
genes and opens new venues for therapy [13,14].
We have used WES to diagnose a cohort of families affected of a wide spectrum of IRD,
including syndromic and non-syndromic cases, recessive and dominant families as well as spo-
radic cases. Initially, a single individual from each family was assessed by WES, followed by
Sanger sequencing as well as cosegregation analysis in available members. A total of 18 out of
33 cases were finally diagnosed, 17 showing causative mutations in already reported genes. In
other 10 families, plausible candidates complying with some of the ACMG/AMP criteria were
identified. Since most of the mutations are novel, including gross deletions and duplications,
our results illustrate the high allelic heterogeneity of IRD and highlight the contribution of pri-
vate mutations. Most important, we propose four new IRD candidates based on the WES data,
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genetic cosegregation, in silico and functional analyses, thus increasing the genetic factors and
cellular pathways underlying neurodegeneration.
Materials and Methods
Subjects
A total of 33 families from Argentina, Saudi Arabia and Spain with patients diagnosed with
IRD were recruited from reference ophthalmological institutions or patient’s associations.
Peripheral blood DNA from patients and available relatives was obtained using the QIAamp
DNA Blood Maxi Kit (Qiagen, Hilden, Germany). Written informed consent from all patients
and relatives was obtained following the tenets of the Declaration of Helsinki. Procedures for
patient recruitment and sample collection were previously approved by the Bioethics Commit-
tee of the University of Barcelona (Barcelona, Spain).
Library preparation and sequencing
Exome sequencing was performed at the Centro Nacional de Ana´lisis Geno´mico (CNAG, Bar-
celona, Spain). Paired-end multiplex libraries were prepared with Illumina TruSeq DNA Sam-
ple Prep kit (Illumina, San Diego, California, USA) and enriched with the Agilent SureSelect
Human AllExon v5 (Agilent, Santa Clara, California, USA). Libraries were loaded onto Illu-
mina flowcells for cluster generation prior to producing 100 base read pairs on a HiSeq2000
instrument. Base calling, quality control and data processing was performed with the Illumina
RTA sequence analysis pipeline as previously described[15]. Detected mutations were verified
by Sanger sequencing. Coverage of the target region and the subset of retinitis related genes
were assessed with DepthOfCoverage from GATK. Subsets of variants falling in the capture
region were obtained using Bedtools[16] and common unix commands.
Prioritization of genetic variants
First, variants that altered the coding region of IRD genes were retrieved when the allelic fre-
quency in public databases (ExAC[17]) was lower than or equal to 1%. Therefore, only infre-
quent null, missense, frameshift and splicing mutations were considered. The second filter was
that the number of identified mutations complied with the expected Mendelian pattern of
inheritance. Third, the missense variants were considered pathogenic when at least two of the
in silico prediction algorithms (MutationTaster[18] SIFT[19], PolyPhen2[20] and CADD[21])
gave a positive score. Selected variants were validated by Sanger sequencing, and confirmed by
cosegregation whenever possible. Pathogenicity was considered according to the ACMG/AMP
standards and guidelines, which take into account.
Detection of chromosomal rearrangements
Coverage analysis was visualized using IGV[22]. For pedigrees 10NCE and 68ORG, cosegrega-
tion of SNPs mapping at the expected deleted region was analysed by PCR amplification and
sequencing as aforementioned. Multiplex Ligation-dependent Probe Amplification (MLPA)
analysis of PRPF31 was carried on 23 individuals of family E4, using the MLPA Retinitis Pig-
mentosa kit SALSA-P235-B2 (MRC Holland, Amsterdam, The Netherlands) with probes for
every PRPF31 exon. MLPA products were separated by capillary electrophoresis and analysed
using the software Coffalyser v8 (MRC Holland) to evaluate CNVs, considering a deletion
when the probe ratio between sample and control was under 0.7, and duplication when it was
over 1.3. The breakpoint of the CRX deletion in family 10NCE was mapped using common
SNPs between CRX and SULT2A1 for PCR-amplification and Sanger-sequencing to identify
Novel IRD Genes and Mutations by WES
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heterozygosity in affected probands (inferring non-deletion) or homozygosity for different
alleles in mother and child (inferring deletion). Adjacent regions were aligned using Pairwise
Sequence Alignment[23]. In family E4, we considered and finally demonstrated a tandem
duplication of PRPF31 exons 2 to 5, by genomic DNA amplification using specific PCR prim-
ers and subsequent sequencing.
Immunodetection of CEP250 in the mouse retina
Adult C57BL/6J mice (IMSR_JAX:000664) were sacrificed in accordance with National
and European regulations. For immunocytochemistry, eyes from adult C57BL/6J mice
(IMSR_JAX:000664) were removed and fixed in 0.1 M phosphate buffer, containing 4% form-
aldehyde for 4 hr at RT. Tissues were cryopreserved overnight in 30% sucrose, embedded in
OCT (Sakura Finetek, Leiden, The Netherlands) and snap-frozen. Cryosections (12 μm) were
incubated with 0.3% Triton X-100 and 2% sheep serum in PBS at 4˚C with the corresponding
primary antibodies: anti-CEP250 1:100 (AB_2076918, Proteintech, Chicago, USA), anti-rho-
dopsin 1D4 1:200 (AB_304874, Abcam, Cambridge, UK) and anti-acetylated α-tubulin 1:3000
(AB_477585, Sigma, St. Louis, Missouri, USA). After incubation with Alexa Fluor 488 and 568
secondary antibodies and DAPI (5 μg/ml) (Sigma) for 2 h at room temperature, slides were
mounted with Mowiol. Confocal images were obtained using a TCS SP2 confocal microscope
(Leica Microsystems, 63× objective, 1.4 NA).
Expression of wt and mutant CEP250 constructs in ARPE19 cells
The mammalian expression vector (pCMV6 backbone) containing the human Wt-CEP250
full-length coding region was obtained from OriGene. Site-directed mutagenesis was then per-
formed on the Wt-CEP250 sequence to generate the A609V mutant (Mt-CEP250). The IT6
epitope (Antibody BCN, Cerdanyola del Vallès, Spain) sequence was fused at the C-terminus
of each coding region. All constructs were sequenced to confirm integrity. Human ARPE-19
cells (1.5x105/well) were plated (40% confluence) onto poly-L-lysine coated coverslips in 1:1
Ham’s F10 and DMEM containing 10% fetal bovine serum and 1% penicillin-streptomycin.
After 24 h, cells were transfected with 0.8 μg/well of either wild-type or mutant CEP250-IT6
expression constructs using Lipofectamine 2000 (Invitrogen, Heidelberg, Germany). On
reaching confluence, cells were deprived of serum for 48 h and then fixed with paraformalde-
hyde for 30 min at room temperature. Coverslips were washed 3 times with PBS and processed
for immunofluorescence staining. Labelling was performed with anti-IT6 antibody 1:100
(kindly provided by Antibody BCN), anti-acetylated α-tubulin 1:3000 (AB_477585, Sigma)
and DAPI nuclear counterstaining. Confocal images were acquired sequentially using a TCS
SP5 confocal microscope (Leica Microsystems, 100× objective, 1.4 NA). Cilia length was mea-
sured using Fiji implementation of Image J[24] and statistical analysis was carried on with
GraphPad Prism.
Results
WES results and genetic analysis of pedigrees
A total of 33 families affected by syndromic and non-syndromic IRD were recruited and ana-
lysed by WES for genetic diagnosis after clinical evaluation. Fourteen patients were simplex
cases with no reported genetic precedent. Four families showed a dominant Mendelian pattern
of inheritance, whereas fourteen were compatible with recessive inheritance. We were able to
identify the genetic cause of the disease in 18 families (out of 33). Moreover, credible candi-
dates are proposed for 10 more cases. Therefore, the strict global diagnostic efficiency was 55%
Novel IRD Genes and Mutations by WES
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to which an additional 30%, based on the identification of plausibly pathogenic variants, could
be added.
For all tested samples (46 individuals belonging to the 33 pedigrees), median coverage in
the whole capture region was 54.90 ± 11.26 (mean 60x) with more than 96% of the targeted
bases covered by 10 or more reads. Equivalent coverage results were observed when looking
only at the IRD genes (based on RetNet[25]). We designed systematic filtering steps for the
selection and prioritization of variants, within the framework proposed by ACMG/AMP stan-
dards and guidelines for evaluating pathogenicity. Only 5 cases remained undiagnosed because
no clear disease-causing candidate was(were) identified.
Overall, the results of the WES analysis globally revealed a mean of 43597 variants in the
whole exome per individual, of which 958 were located in known IRD genes. In several fami-
lies, patients were carriers of additional IRD-pathogenic recessive mutations in heterozygosis,
which could certainly add to the phenotypic severity and variability.
Detailed genotype analysis
The results of WES are shown in Table 1. Concerning the syndromic cases, only one pedigree
(79ORG), affected by Usher, had a correct clinical diagnosis. The two other pedigrees, previ-
ously diagnosed as non-syndromic IRD cases, turned out to be syndromic after WES-mediated
identification of the causative genes and mutations. A young patient (simplex case, 64ORG)
carried two mutations in the PHYH gene, encoding a peroxisomal enzyme associated to the
Refsum syndrome. Retinitis Pigmentosa (RP) is an early-onset symptom of this syndrome fol-
lowed later on by other pathological traits (e.g. deafness, skin alterations, peripheral neuropa-
thy and ataxia). One allele was a frameshift mutation leading to protein truncation, and the
second allele (P223R) caused a damaging missense substitution in a conserved residue embed-
ded in a highly evolutionarily conserved PhyH domain (S1 Fig). Clinical and metabolic re-
evaluation of the pre-symptomatic patient (phytanic acid levels in serum measured by gas
chromatography were 32 times the normal threshold values) totally confirmed the Refsum
syndrome diagnosis, which had been previously unnoticed, and allowed to implement a pre-
ventive treatment for late-onset Refsum disorder traits, by decreasing the ingestion of phytanic
acid. According to the clinician, the patient has since greatly improved in some phenotypic
traits, mainly reducing the ichthyosis bursts and the anosmia. Similarly, two novel mutations
in the C21orf2 gene, a frameshift and a damaging missense substitution in a highly conserved
position within the leucine-rich repeats (S1 Fig), re-classified a non-syndromic cone-rod dys-
trophy to the recently reported spondylometaphyseal dysplasia syndrome (SMD), where RP is
associated to severe thoracic abnormalities. Patients in this family (A10) showed both RP and
skeletal dysplasia, initially considered as unlinked traits. Again, our results prompted clinical
re-evaluation, and supported C21orf2 association to this syndrome[26].
With respect non-syndromic cases, WES identified the causative mutations in IRD reported
genes in 21 cases/families (Table 1). Mild mutations in syndromic genes have already been
reported as causative for non-syndromic phenotypes. This is also the case in our cohort for
mutations in BBS2 (pedigree A18), CEP290 (pedigree 65ORG) and USH2A (51ORG and
73ORG). The BBS2 and CEP290mutations are novel, contrary to those of USH2A. Mutations
in CEP290 are associated to severe ciliopathies, except for a prevalent intronic mutation that
affects the splicing pattern and decreases the pool of full-length molecules. Remarkably, the
two mutations here identified in heterozygosis expand the panoply of non-syndromic CEP290
mutations. Since one allele is null (Table 1), the missense substitution H50Y, residing in a
non-strictly conserved peptide stretch within the homo/heterodimerization domain, should be
relatively mild (S1 Fig).
Novel IRD Genes and Mutations by WES
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Although most of the identified alleles were novel mutations in genes already assigned to a
defined clinical entity, clinical assignment was sometimes reconsidered after genetic diagnosis,
e.g. patients previously assigned as arLCA were re-classified as affected from autosomal reces-
sive achromatopsia, after identification of mutations in CNGA3 and CNGB3.
Simplex cases are usually assumed to be recessive. However, in our cohort, four simplex
patients (nearly 20%) were either hemizygous or heterozygous for genes associated to X-linked
or dominant mutations. For instance, a male patient showed a pathogenic indel in exon 7 of
the RPGR gene. Besides, we identified a heterozygous deletion in exon 1 of UNC119 in the
82ORG case, further supporting this gene as candidate for dominant IRD. Remarkably,
reported dominant mutations in CNGB3 and PDE6B were respectively identified in families
22ORG and 39ORG (Fig 1). However, this mutational assignment is controversial according
to our results, since cosegregation analysis showed other carrier members that were unaffected,
even after clinical re-evaluation. Notably, the affected individuals also carried heterozygous
missense mutations in other reported genes, which were absent in the non-affected carriers of
CNGB3 and PDE6B dominant mutations (Fig 1, Table 1), suggesting that incomplete pene-
trance could be due to independent segregation of two different mutations, only detectable
after WES.
Fig 1. Segregation of mutations in selected pedigrees. Pedigrees bearing new IRD candidates and chromosomal rearrangements are
shown. Pedigrees where mutations in several genes co-segregate with the disease are also depicted. Alleles and carrier status are indicated
below each analysed individual. Grey symbols (in H) shown patients bearing a different chromosomal rearrangement. The rest of the
pedigrees are available as S3 Fig.
doi:10.1371/journal.pone.0168966.g001
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Large deletions and chromosomal rearrangements were identified by WES in three families.
In the arRP 68ORG family, a single nonsense pathogenic allele in the EYS gene was first identi-
fied. A careful coverage analysis along all the EYS exons unveiled a novel deletion encompass-
ing the initial 10 exons as a second allele. This deletion was confirmed by homozygous SNP
haplotype in the affected mother and carrier son (Fig 2). In two very large dominant pedigrees,
WES did not render any plausible candidate. In family 10NCE, a very rare and mild polymor-
phism mapping in a gene adjacent to CRX, cosegregated with the disease. A careful coverage
Fig 2. Identification of EYS and CRX deletions. A-F) Two different gross heterozygous deletions in genes EYS and CRX were
respectively identified as the causative mutation in families 68ORG and 10NCE. The probands (B and D) showed a reduction in the
coverage of some exons compared to the respective controls (A and C). The segregation of SNPs located in the expected deleted region
showing that mother and child were homozygous for different alleles is indicated below. (E and F). G) Chromosomal deletion in family
10NCE is defined by genotyping common SNPs between CRX and SULT2A1 genes in the affected probands. Heterozygous SNPs are
indicated by4, whereas SNPs where mother and child were homozygous for different alleles are indicated byr. Adjacent breakpoint
regions with high sequence similarity are boxed in orange and green and preserved sequences in the rearranged allele are indicated with
orange and green lines. H) Sequence chromatogram of the rearranged allele is shown below. Alignment of the highly similar sequences of
CRX intron 2 (CRX IVS2) and the intragenic region involved in the rearrangement is also indicated. Again, orange and green lines are the
adjacent sequences to the breakpoint, which is indicated by a red square.
doi:10.1371/journal.pone.0168966.g002
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analysis of CRX in the patients identified a heterozygous deletion encompassing exons 3 and 4
(Fig 2), which was finely mapped by genomic DNA PCR and Sanger sequencing. The flanking
regions shared high sequence similarity probably account for illegitimate homologous recom-
bination. This result prompted us to re-evaluate the WES coverage data in all dominant
unsolved pedigrees. Remarkably, the large E4 pedigree showed an unusual chromosomal rear-
rangement (Fig 3), since one side of the family showed increased exon coverage in the PRPF31
gene, whereas the other side of the family showed a decrease. To confirm and map the exons
involved, a complete PRPF31 MLPA analysis was performed and two rearranged pathogenic
alleles segregating in the same family were identified: an internal duplication affecting exons 2
to 5 (inclusive) and a gross deletion involving exon 1 to 13 of PRFP31. Since WES coverage in
the upstream genes was also decreased, this deletion could include nearby genes, at least TFPT
NDUFA3, and a part of OSCAR.
New candidates
When no pathogenic variants were identified in IRD genes, we expanded the mutational
search to all the WES data. Following the ACMG/AMP guidelines, four novel recessive candi-
dates were proposed based on the mutational effect at the molecular level, the predicted in sil-
ico pathogenicity and the assigned gene function. These four candidates are SEMA6B and
three members of the centrosomal/ciliary protein family CEP78,CEP250, SCLT1. In all these
cases, the clinical assessment of the patients was only RP (S2 Fig).
SEMA6B, mutated in homozygosis in a simplex case, is highly expressed in the development
of the murine retina and belongs to a family of transmembrane proteins with multiple roles in
signalling and axon guidance[40,41]. The G165R missense variant is located within the sema-
phorin domain, close to the plexin binding sites. This substitution changes the size and charge
of a conserved amino acid in vertebrates (S1 Fig), and is predicted in silico as pathogenic
(Table 1). Moreover, the mutation strictly cosegregates with the disease in the family (Fig 1).
CEP78 encodes a centrosomal protein of unknown function. Our rationale behind propos-
ing this gene as probably causative of arRP is: i) affected individuals are homozygous for the
mutation, which causes a frameshift that generates a truncated protein, ii) mutations on several
centrosomal protein genes cause IRD, and finally, iii) cosegregation with the disease in the
family (Fig 1).
SCLT1 was also proposed to be causative of early-onset RP since: i) this gene causes oro-
facial-digital syndrome type IX, a very rare and severe ciliopathy with congenital eye defects;
ii) patients are heterozygotes for one missense and one splicing altering mutations; and indeed
iii) the variants cosegregate with the disease in the family (Fig 1). The missense mutation,
R276H, alters a relevant residue in the Smc multidomain (chromosome segregation ATPase
domain) shared with many other proteins, many of them centrosomal, involved in cell cycle
control[42]. Therefore, we here describe a new phenotype for a previously reported ciliopathy
gene.
Concerning CEP250, previously associated to atypical Usher syndrome, the homozygous
missense A609V is a seemingly mild amino acid substitution embedded in a long evolution-
arily conserved stretch of the Smc domain. Its presumed pathogenicity was based on in silico
prediction algorithms and cosegregation with the disease. However, since this substitution
only affected size but not the charge or other chemical properties of the amino acid, we
decided to test CEP250 expression in the retina, and assay the phenotypic effects of the muta-
tion. Endogenous CEP250 in mouse retinal cryosections (P60) was mostly detected in the
outer photoreceptor segment (Fig 4A), supporting its localization in the photoreceptor axo-
neme (Fig 4B). Other centrosomal proteins that cause IRD, such as OFD1, share a similar
Novel IRD Genes and Mutations by WES
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Fig 3. Identification of independent PRPF31 deletion and duplication segregating in pedigree E4. Exome
data indicated significant coverage differences of PRPF31 exons in the E4 family, pointing to chromosomal
rearrangements. Some patients (A) showed higher coverage in exons 2–5 compared to a control sample (C)
whereas patients from another family branch showed a significant decrease of exons 1–13 (B). CRX, located a few
Mb away from PRPF31 gene, was used as a control gene (D-F). MLPA analysis confirmed a nearly full deletion of
PRPF31 (exons 1 to 13) in some patients of the family (G) and an internal duplication involving exons 2 to 5 in other
affected members (H) (shown in grey in Fig 1). I) Chromosomal region of PRPF31 involved in the duplication, where
the duplicated exons are coloured in orange. Green and red lines below indicate the extent of the duplication.
Chromatogram of the rearranged allele is shown below. Alignment of the flanking sequences (boxed in orange and
Novel IRD Genes and Mutations by WES
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green) involved in the rearrangement shows no clear homology. Orange and green lines are the adjacent
sequences to the breakpoint, which is indicated by a red square.
doi:10.1371/journal.pone.0168966.g003
Fig 4. Immunodetection of endogenous CEP250 in mouse retinal cryosections. Immunostaining of
CEP250 with rod photoreceptor marker rhodopsin (A) and acetylated α-tubulin (B). CEP250 stained mainly
the outer segment of photoreceptors (CEP250 is in red, Rhodopsin and acetylated-α-tubulin in green,
nuclear counterstaining by DAPI in blue). Cells expressing A609V CEP250-IT6 show longer cilia. (C)
Wild-type (Wt) and mutant (Mt) CEP250-IT6 (green) co-localize with acetylated α-tubulin (red) to primary
cilia in serum-starved ARPE-19 cells. Immunolabelling of CEP250 and acetylated α-tubulin show longer cilia
in cells transfected with the mutant A609V CEP250-IT6 compared to Wt-CEP250-IT6. (D) Cilia length
quantification in Wt- and Mt- CEP250-IT6 transfected cells. Graph shows that cilia from cells expressing
mutant CEP250 were one third longer than cilia from cells expressing Wt-CEP250 (n>30). Mean and error
are shown. *** indicates high statistical significance by the t-Student test, p<0.001. (E) Distribution of cilium
length represented as a cumulative frequency chart of the percentage of total cilia. OS—photoreceptor
outer segments; CC—connecting cilium; IS—photoreceptor inner segments; ONL—outer nuclear layer; INL
—inner nuclear layer; GCL—ganglion cell layer.
doi:10.1371/journal.pone.0168966.g004
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localization pattern in the retina[43]. Furthermore, localization of the wild-type and A609V
CEP250 proteins was studied in transfected human ARPE19 cells where cilia formation was
promoted after serum-starvation. To avoid steric hindrance we used a new epitope specifically
designed for innocuous protein tagging (IT6, Antibody BCN). The endogenous CEP250
expression was not silenced, but the use of the IT6 antibody allowed us to identify transfected
cells. Remarkably, cells expressing the A609V CEP250 (Mt-CEP250) protein consistently
showed elongated primary cilia compared to Wt-CEP250 transfected cells (Fig 4C). Cilium
length was measured and quantified. On average, Mt-CEP250 cilia were one third longer than
the wild-type counterparts, with high statistical significance (Fig 4D and 4E). Overall, our
results support involvement of CEP250 in retinal ciliogenesis, and highlight this gene as a new
IRD candidate.
In many patients, besides the causative variants, additional rare variants, predicted as dam-
aging by at least two in silico algorithms, were identified in known IRD genes. These variants
were mostly unreported in the Human Gene Mutation Database[44]. We did not consider
them as causative on the grounds of heterozygosis in recessive probands, lack of cosegregation
in dominant cases, relative frequency of homozygotes in the reported normal population
(ExAC), and because of the identification of two mutations in a more plausible pathogenic
candidate in the proband. We deem these variants (S1 Table) are likely modifiers of the pheno-
typic traits of the patients.
Discussion
The WES analysis (mean coverage around 60x) of our cohort of 33 unrelated families has iden-
tified the causative gene in 18 cases and proposed a plausible candidate in 10 additional cases.
Only five cases (15%) remained unsolved. Overall, we have identified 21 unreported mutations
in known IRD genes and additionally proposed four novel candidates, CEP250,CEP78,
SEMA6B and SCLT1. Functional support for the pathogenicity of the homozygous A609V mis-
sense mutation in CEP250 is also provided. Our prioritized analysis of WES is very efficient
and comparable to other NGS-based methods, such as NGS-customized targeted sequencing
[45]. However, syndromic genes which would be rarely included in gene panels can be easily
analyzed. Besides, when no mutations in the prioritized genes are found, the search for patho-
genic variants in new candidates can be performed using the same data by changing the search
parameters. This new search can: 1) highlight presymptomatic patients of severe late-onset dis-
orders, 2) uncover new phenotype-genotype associations in milder alleles of syndromic genes,
3) propose new IRD candidates.
Concerning clinical re-evaluation, pathogenic variants in PHYH (a syndromic gene usually
absent in customized targeted panels) were identified in patient 64ORG, which questioned the
initial diagnosis of RP, informing the clinician and the patient of the disease before other
Refsum syndrome traits appeared and most importantly, leading to a preventive treatment. In
family A10, the mutations in C21orf2 also changed the initial CRD diagnosis to axial spondylo-
metaphyseal dysplasia, associating RP to previously unrelated skeletal traits. Besides, WES also
uncovered new mutations in very low prevalence genes, not usually included in targeted pan-
els, e.g. UNC119, in our cohort [11,46,47].
The ever increasing number of novel mutations—even in previously reported genes—
highlighted by massive sequencing is changing the scenario of established genotype-phenotype
correlations and patterns of mendelian inheritance[48] and calls for an in-depth re-evaluation
of our genetic knowledge[49]. Double heterozygosity of private mutations may be more fre-
quent than expected in recessive cases of “rare-but-not-so-rare” diseases (prevalence 1:3000),
barring the cases of highly consanguineous populations, where homozygosity mapping has
Novel IRD Genes and Mutations by WES
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been the basic genetic tool. On the other hand and concerning dominant cases, two previously
reported dominant mutations affected a single member of the family in contrast to a larger
number of asymptomatic carriers. These contradictory results might be explained by either
misassignment of the pathogenicity of the genetic variant or incomplete gene screening in past
reports.
We have identified several pathogenic duplications and deletions of large chromosomal
regions in already reported genes in two dominant (affecting CRX and PRPF31) and in one
recessive pedigree (altering EYS). Remarkably, in the E4 dominant pedigree (Fig 1), both a
deletion and a duplication in PRPF31 were identified in two branches of the same family.
PRPF31 pathogenic alleles due to internal deletions/duplications are not infrequent and
amount up to 20% [50]. The remarkable finding is that two of such highly disruptive chromo-
somal rearrangements segregated in two branches of the same family. The rearranged genomic
regions differed in size, involved different exons, and did not share any apparent flanking
sequence, which would suggest independent genetic events (Fig 3). These structural mutations
are still difficult to identify in heterozygosis unless specific dosage analysis tests or careful eval-
uation of coverage are performed. However, our results strongly support the relevant contribu-
tion of structural variation to disease (50% of our dominant cases). We deem it likely that the
list of pathogenic alleles involving chromosomal rearrangements will increase in the following
years.
Four new candidates for non-syndromic IRD were also highlighted by WES. Remarkably,
three of them are related to cilia and ciliogenesis (SCLT1, CEP250 and CEP78). Severe gene
mutations involved in ciliogenesis are either lethal or cause severe syndromic ciliopathies,
whereas milder alleles show a more restricted phenotype and affect only particular ciliated
organs (retina, cochlea, renal tubules. . .)[51], e.g. CEP290 cause Leber Congenital Amaurosis
[52], and OFD1 is responsible for severe X-linked RP[53] as well as oro-facial-digital syndrome
I, characterized by craniofacial, oral and skeletal abnormalities[54] or other syndromic dis-
eases[55]. We have identified a mild missense substitution and a mutation in the consensus
acceptor splicing site (intron 10) of SCLT1, another member of the oro-facial-digital syndrome
gene family[56]. These previous reports highlight SCLT1 as a new arRP candidate, and illus-
trate the tenuous line between genes involved in syndromic and non-syndromic disorders.
Our WES results further support the involvement of two CEP proteins in IRD. A homozy-
gous frameshift mutation in CEP78 in two siblings of a consanguineous family pointed directly
to this gene as a plausible new candidate for arRP. Concerning CEP250 involvement in retinal
neurodegeneration, previous reports described a close interaction with NEK2 (a centrosomal
RP gene)[57,58], and it was also suggested as a modifier gene in an atypical Usher syndrome
family where nonsense mutations in CEP250 in homozygosis and in C2orf71 in heterozygosis
showed an additive effect[59]. Our results support that a homozygous missense mutation in
CEP250may cause arRP by altering the structure and length of cilia. Of note, in this family
another arRP mutation segregated in heterozygosis, the reported C948Y CRB1mutation (fre-
quent in the Spanish population[60,61]), which could also contribute to the severity of the
phenotype.
WES data allows the identification of the causative mutations plus incidental findings in
other relevant retinal genes. When focusing solely on IRD genes, many patients are heterozy-
gous carriers of both, known pathogenic recessive alleles (average of 0.3 mutations per
patient), and rare predicted pathogenic variants (average of 5.25 variants per patient). Similar
values of heterozygous carriers of pathogenic variants in IRD genes have been identified in
control individuals (1:4) after NGS-analysis[62]. Most of these recessive alleles correspond to
Novel IRD Genes and Mutations by WES
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prevalent mutations in the geographical population of origin and thus, heterozygous carriers
should be expected among controls. Therefore, databases of human genetic variation of
healthy individuals used as controls for new pathogenic variants may in fact contain true
mutations. Indeed, caution should be recommended in genetic diagnosis to avoid misinterpre-
tation of these findings. On the other hand, when drawing genotype-phenotype correlations in
relation with the clinical prognosis, these additional recessive genetic variants might act as
hypomorphic alleles that induce or enhance the phenotypic effects of the causative mutations,
accounting for the phenotypic differences within carriers of the same mutations. For instance,
the 22ORG pedigree showed heterozygous variants in CRB1 and ROM1 besides the reported
dominant mutation in CNGB3. The patient bears the CNGB3 mutation together with the
ROM1 mutation, whereas the non-penetrant sibling only carries the CNGB3mutation (Fig 1).
Similarly, the patient in family 39ORG carried a heterozygous mutation in USH2A additionally
to the previously reported dominant mutation in PDE6B, in contrast to several non-penetrant
members of the family who only carried the PDE6B pathogenic variant. Therefore, the defini-
tion of modifier or susceptibility genes may be widened to include heterozygous mutations in
already known causative genes, which probably underlie reduced penetrance and variable
expressivity, and calls for reconsideration of the concepts of causative, susceptibility and modi-
fier genes.
Overall, our work supports WES as a highly informative and effective approach for patient
molecular diagnosis in retinal dystrophies provided there is qualified genetic counselling.
Besides, our data contributes to the databases that aim to address personalized genotype-phe-
notype correlations. Genomic data from carefully clinically diagnosed patients are required to
build a comprehensive human genomic landscape and elucidate how the interactions and
complex tradeoffs between mutations, additional genetic variants—and environmental factors
—tip the scales towards pathogenicity or resilience to disease.
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S1 Fig. Conservation of missense mutations. Clustalw alignment of protein sequences of dif-
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Pigmentosa.
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S3 Fig. Cosegregation analysis of the mutations identified by WES in our cohort (comple-
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